Cargando…

Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival

BACKGROUND: Information about survival by stage in bladder cancer is scarce, as well as about survival of non-invasive bladder cancer. The aims of this study are: 1) to find out the distribution of bladder cancer by stage; 2) to determine cancer-specific survival by stage of bladder cancer; 3) to id...

Descripción completa

Detalles Bibliográficos
Autores principales: Ripoll, J., Ramos, M., Montaño, J., Pons, J., Ameijide, A., Franch, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186217/
https://www.ncbi.nlm.nih.gov/pubmed/34098901
http://dx.doi.org/10.1186/s12885-021-08418-y
_version_ 1783704916609466368
author Ripoll, J.
Ramos, M.
Montaño, J.
Pons, J.
Ameijide, A.
Franch, P.
author_facet Ripoll, J.
Ramos, M.
Montaño, J.
Pons, J.
Ameijide, A.
Franch, P.
author_sort Ripoll, J.
collection PubMed
description BACKGROUND: Information about survival by stage in bladder cancer is scarce, as well as about survival of non-invasive bladder cancer. The aims of this study are: 1) to find out the distribution of bladder cancer by stage; 2) to determine cancer-specific survival by stage of bladder cancer; 3) to identify factors that explain and predict the likelihood of survival and the risk of dying from these cancers. METHODS: Incident bladder cancer cases diagnosed between 2006 and 2011 were identified through the Mallorca Cancer Registry. Inclusion criteria: cases with code C67 according to the ICD-O 3rd edition with any behaviour and any histology, except lymphomas and small cell carcinomas. Cases identified exclusively through the death certificate were excluded. We collected the following data: sex; age; date and method of diagnosis; histology according to the ICD-O 3rd edition; T, N, M and stage at the time of diagnosis; and date of follow-up or death. End point of follow-up was 31 December 2015. Multiple imputation (MI) was performed to estimate cases with unknown stage. Cases with benign or indeterminate behaviour were excluded for the survival analysis. Actuarial and Kaplan-Meier methods and Cox regression models were used for survival analysis. RESULTS: One thousand nine hundred fourteen cases were identified. 14% were women and 65.4% were 65 years or older. 3.9% had no stage (benign or undetermined behaviour) and 11.5% had unknown stage. After MI, 37.5% were in stage Ta (non-invasive papillary carcinoma), 3.2% in stage Tis (carcinoma in situ), 34.3% in stage I, 11.7% in Stage II, 4.3% in stage III, and 9.0% in stage IV. Survival was 76% at 5 years. Survival by stage: 98% at stage Ta, 90% at stage Tis, 85% at stage I, 45% at stage II, 35% at stage III, and 7% at stage IV. The Cox model showed that age, histology, and stage, but not sex, were associated with survival. CONCLUSION: Bladder cancer survival vary greatly with stage, among both non-invasive and invasive cases. The percentage of non-invasive cancers is high. Stage, age, and histology are associated to survival.
format Online
Article
Text
id pubmed-8186217
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81862172021-06-10 Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival Ripoll, J. Ramos, M. Montaño, J. Pons, J. Ameijide, A. Franch, P. BMC Cancer Research Article BACKGROUND: Information about survival by stage in bladder cancer is scarce, as well as about survival of non-invasive bladder cancer. The aims of this study are: 1) to find out the distribution of bladder cancer by stage; 2) to determine cancer-specific survival by stage of bladder cancer; 3) to identify factors that explain and predict the likelihood of survival and the risk of dying from these cancers. METHODS: Incident bladder cancer cases diagnosed between 2006 and 2011 were identified through the Mallorca Cancer Registry. Inclusion criteria: cases with code C67 according to the ICD-O 3rd edition with any behaviour and any histology, except lymphomas and small cell carcinomas. Cases identified exclusively through the death certificate were excluded. We collected the following data: sex; age; date and method of diagnosis; histology according to the ICD-O 3rd edition; T, N, M and stage at the time of diagnosis; and date of follow-up or death. End point of follow-up was 31 December 2015. Multiple imputation (MI) was performed to estimate cases with unknown stage. Cases with benign or indeterminate behaviour were excluded for the survival analysis. Actuarial and Kaplan-Meier methods and Cox regression models were used for survival analysis. RESULTS: One thousand nine hundred fourteen cases were identified. 14% were women and 65.4% were 65 years or older. 3.9% had no stage (benign or undetermined behaviour) and 11.5% had unknown stage. After MI, 37.5% were in stage Ta (non-invasive papillary carcinoma), 3.2% in stage Tis (carcinoma in situ), 34.3% in stage I, 11.7% in Stage II, 4.3% in stage III, and 9.0% in stage IV. Survival was 76% at 5 years. Survival by stage: 98% at stage Ta, 90% at stage Tis, 85% at stage I, 45% at stage II, 35% at stage III, and 7% at stage IV. The Cox model showed that age, histology, and stage, but not sex, were associated with survival. CONCLUSION: Bladder cancer survival vary greatly with stage, among both non-invasive and invasive cases. The percentage of non-invasive cancers is high. Stage, age, and histology are associated to survival. BioMed Central 2021-06-07 /pmc/articles/PMC8186217/ /pubmed/34098901 http://dx.doi.org/10.1186/s12885-021-08418-y Text en © The Author(s) 2021, corrected publication 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Ripoll, J.
Ramos, M.
Montaño, J.
Pons, J.
Ameijide, A.
Franch, P.
Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival
title Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival
title_full Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival
title_fullStr Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival
title_full_unstemmed Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival
title_short Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival
title_sort cancer-specific survival by stage of bladder cancer and factors collected by mallorca cancer registry associated to survival
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186217/
https://www.ncbi.nlm.nih.gov/pubmed/34098901
http://dx.doi.org/10.1186/s12885-021-08418-y
work_keys_str_mv AT ripollj cancerspecificsurvivalbystageofbladdercancerandfactorscollectedbymallorcacancerregistryassociatedtosurvival
AT ramosm cancerspecificsurvivalbystageofbladdercancerandfactorscollectedbymallorcacancerregistryassociatedtosurvival
AT montanoj cancerspecificsurvivalbystageofbladdercancerandfactorscollectedbymallorcacancerregistryassociatedtosurvival
AT ponsj cancerspecificsurvivalbystageofbladdercancerandfactorscollectedbymallorcacancerregistryassociatedtosurvival
AT ameijidea cancerspecificsurvivalbystageofbladdercancerandfactorscollectedbymallorcacancerregistryassociatedtosurvival
AT franchp cancerspecificsurvivalbystageofbladdercancerandfactorscollectedbymallorcacancerregistryassociatedtosurvival